Efficacy of ceftolozane in a murine model of Pseudomonas aeruginosa acute pneumonia: In vivo antimicrobial activity and impact on host inflammatory response

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 1, 2013, Pages 177-183

  Jacqueline, Cédric ^a   Roquilly, Antoine ^a   Desessard, Cyndie ^a   Boutoille, David ^a   Broquet, Alexis ^a   Le Mabecque, Virginie ^a   Amador, Gilles ^a   Potel, Gilles ^a   Caillon, Jocelyne ^a   Asehnoune, Karim ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

Cephalosporins; Cytokines; Inflammation; Lung

Indexed keywords

CEFTAZIDIME; CEFTOLOZANE; IMIPENEM; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 2; MEROPENEM; MYELOPEROXIDASE; PIPERACILLIN PLUS TAZOBACTAM; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL LOAD; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOLOGY; IN VIVO STUDY; LUNG; LUNG ENDOTHELIUM; LUNG INJURY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPHIL; NONHUMAN; PSEUDOMONAS PNEUMONIA; TIME TO MAXIMUM PLASMA CONCENTRATION;

ACUTE DISEASE; ANIMALS; ANTI-INFECTIVE AGENTS; CEFTAZIDIME; CEPHALOSPORINS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; INFLAMMATION; MICE; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME;

EID: 84871251044     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks343     Document Type: Article

References (35)

1. Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 2001; 47: 247-50.
2. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34: 634-40.
3. Maltezou HC. Metallo-b-lactamases in Gram-negative bacteria: introducing the era of pan-resistance? Int J Antimicrob Agents 2009; 33: 405.e1-7.
4. Livermore DM, Mushtaq S, Ge Y. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus b-lactamaseproducing Enterobacteriaceae. J Antimicrob Chemother 2010; 65: 1972-4.
5. Giske CG, Ge J, Nordmann P. Activity of cephalosporin CXA-101 (FR264205) and comparators against extended-spectrum-b-lactamaseproducing Pseudomonas aeruginosa. J Antimicrob Chemother 2009; 64: 430-1.
6. Takeda S, Ishii Y, Hatano K et al. Stability of FR264205 against AmpC b-lactamase of Pseudomonas aeruginosa. Int J Antimicrob Agents 2007; 30: 443-5.
7. Takeda S, Nakai T, Wakai Y et al. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2007; 51: 826-30.
8. Sadikot RT, Blackwell TS, Christman JW et al. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 2005; 171: 1209-23.
9. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Ninth Edition: Approved Standard M07-A9. CLSI, Wayne, PA, USA, 2011.
10. Ge Y, Whitehouse MJ, Friedland I et al. Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. Antimicrob Agents Chemother 2010; 54: 3427-31.
11. LeBel M, Barbeau G, Vallee F et al. Pharmacokinetics of ceftazidime in elderly volunteers. Antimicrob Agents Chemother 1985; 28: 713-5.
12. Sörgel F, Kinzig M. Pharmacokinetic characteristics of piperacillin/tazobactam. Intensive Care Med 1994; 20 Suppl 3: S14-20.
13. Bulik CC, Tessier PR, Keel RA et al. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin/tazobactam using human simulated exposures against phenotypically diverse Gram-negative organisms. Antimicrob Agents Chemother 2012; 56: 544-9.
14. Acred P. Therapeutic and kinetic properties of ceftazidime in animals. Infection 1983; 11 Suppl 1: S44-8.
15. dos Santos KV, Nicoli JR, Martins WA et al. Comparative activity of ertapenem and piperacillin-tazobactam in a murine systemic infection model with Bacteroides fragilis and Escherichia coli. J Med Microbiol 2007; 56: 1576-9.
16. Roquilly A, Gautreau L, Segain JP et al. CpG-ODN and MPLA prevent mortality in a murine model of post-hemorrhage-Staphylococcus aureus pneumonia. PLoS One 2010; 5: e13228.
17. Boutoille D, Marechal X, Pichenot M et al. FITC-albumin as a marker for assessment of endothelial permeability in mice: comparison with 125I-albumin. Exp Lung Res 2009; 35: 263-71.
18. Balamayooran G, Batra S, Fessler MB et al. Mechanisms of neutrophil accumulation in the lungs against bacteria. Am J Respir Cell Mol Biol 2010; 43: 5-16.
19. Hsueh PR, Tseng SP, Teng LJ et al. Pan-drug-resistant Pseudomonas aeruginosa causing nosocomial infection at a university hospital in Taiwan. Clin Microbiol Infect 2005; 11: 670-3.
20. Quale J, Bratu S, Gupta J et al. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2006; 50: 1633-41.
21. Juan C, Zamorano L, Pérez JL et al. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother 2010; 54: 846-51.
22. Moyá B, Zamorano L, Juan C et al. Activity of a new cephalosporin, CXA-101 (FR264205), against b-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob Agents Chemother 2010; 54: 1213-7.
23. Werner U, Szelenyi I. Measurement of MPO activity as model for detection of granulocyte infiltration in different tissues. Inflamm Res 1992; 36: 101-3.
24. Mizgerd JP. Molecular mechanisms of neutrophil recruitment elicited by bacteria in the lungs. Semin Immunol 2002; 14: 123-32.
25. Bianchi SM, Prince LR, McPhillips K et al. Impairment of apoptotic cell engulfment by pyocyanin, a toxic metabolite of Pseudomonas aeruginosa. Am J Respir Crit Care Med 2008; 177: 35-43.
26. Mizgerd JP. Acute lower respiratory tract infection. N Engl J Med 2008; 358: 716-27.
27. Richman-Eisenstat J. Cytokine soup: making sense of inflammation in cystic fibrosis. Pediatr Pulmonol 1996; 21: 3-5.
28. Saperstein S, Huyck H, Kimball E et al. The effects of interleukin-1b in tumor necrosis factor-a-induced acute pulmonary inflammation in mice. Mediators Inflamm 2009; 2009: 958658.
29. Hilliard JJ, Melton JL, Hall L et al. Comparative effects of carbapenems on bacterial load and host immune response in a Klebsiella pneumoniae murine pneumonia model. Antimicrob Agents Chemother 2011; 55: 836-44.
30. Mizgerd JP, Skerrett SJ. Animal models of human pneumonia. Am J Physiol Lung Cell Mol Physiol 2008; 294: L387-98.
31. Garvy BA, Harmsen AG. The importance of neutrophils in resistance to pneumococcal pneumonia in adult and neonatal mice. Inflammation 1996; 20: 499-512.
32. Hampton MB, Kettle AJ, Winterbourn CC. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 1998; 92: 3007-17.
33. Gaut JP, Byun J, Tran HD et al. Myeloperoxidase produces nitrating oxidants in vivo. J Clin Invest 2002; 109: 1311-9.
34. Moyá B, Zamorano L, Juan C et al. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010; 54: 3933-7.
35. Qiu H, KuoLee R, Harris G et al. High susceptibility to respiratory Acinetobacter baumannii infection in A/J mice is associated with a delay in early pulmonary recruitment of neutrophils. Microbes Infect 2009; 11: 946-55.